Most Read

Under the agreement, twoXAR will use its proprietary artificial intelligence (AI ) technology to identify a set of lead compounds which demonstrate a novel mechanism of action and

The fundraise was co-led by new investors OrbiMed Advisors and Arix Bioscience plc and included investment from RA Capital and Rock Springs Capital. Existing investors New Enterprise Associates,

Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. They are characterized clinically by progressive ataxia symptoms, including difficulties with balance, speech, and coordination, and

Hemlibra can be used in all age groups, and can also now be used at multiple dosing options (once weekly, every two weeks, or every four weeks) for

Dupixent can be used with or without topical corticosteroids. “For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control

The Phase 3 global, randomized, double-blind trial is evaluating CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with

Providing unparalleled levels of transparency and visibility, it empowers pharma actors to efficiently detect, act upon and ultimately prevent costly temperature excursions – currently causing billions worth of

On March 2nd, 2019, TaiwanJ announced that its JKB-122, an effective phase 2 nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) drug candidate, had been successfully licensed out to

Proceeds from the financing will be used to advance the company’s development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific